RxDoctor Payments Data

Brian McLeod, MD

Urology · Brooklyn, CTNPI 1447255963

Payments from drug & device makers

$986in general payments, 2019–2025

Across 35 payments — averaging $28.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$184
  • Sumitomo Pharma America, Inc.$147
  • Pfizer$123
  • Astellas Pharma US Inc$119
  • Myovant Sciences Inc.$106
  • Rochester Medical Corporation$93
  • plus $214 from 7 others

What the payments were for

  • Travel & lodging$17318%
  • Food & beverage$53754%
  • Education$27728%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$986 in reported general payments places this provider in the 35th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$192,072
Medicare patients
533
Services billed
8,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide40$180,554
MyrbetriqMirabegron186$171,254
OrgovyxRelugolix38$88,520
GemtesaVibegron48$33,575
Tamsulosin Hcl1,802$22,963
Mirabegron ErMirabegron29$21,343
Methenamine Hippurate270$14,716
Finasteride959$10,540
Testosterone47$8,995
Oxybutynin Chloride ErOxybutynin Chloride441$7,539
Solifenacin Succinate120$5,832
Alfuzosin Hcl ErAlfuzosin Hcl210$4,798
Desmopressin Acetate72$4,654
NitrofurantoinNitrofurantoin Macrocrystal113$4,519
Silodosin70$4,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$119$351,808226 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$147$122,09586 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 156 urology providers in Connecticut.

Other urology in Brooklyn

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →